Maravai LifeSciences (MRVI) vs First Tracks Biotherapeutics (TRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Maravai LifeSciences is the larger company by market cap ($1.81 billion vs $1.75 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRVI | TRAX |
|---|---|---|
| Share price | $6.98 | $41.64 |
| Market cap | $1.81B | $1.75B |
| 1-day change | -2.92% | -6.34% |
| YTD return | +114.77% | — |
| 1-year return | +86.13% | — |
| 5-year return | -83.18% | — |
| EPS (TTM) | $-0.44 | $-4.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $185.74M | — |
| Revenue growth (YoY) | -28.34% | — |
| Net income (latest FY) | $-130.77M | — |
| Gross margin | 18.30% | — |
| Operating margin | -115.89% | — |
| Net margin | -70.41% | — |
| 52-week high | $9.42 | $54.78 |
| 52-week low | $2.80 | $14.72 |
| Distance from 52-week high | -25.90% | -23.99% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +38.11% | +80.52% |
| Average volume | 2.72M | 826.70K |
| Shares outstanding | 149.25M | 42.02M |
| Employees | 410 | 104 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 410 employees
About First Tracks Biotherapeutics
TRAX stock →First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 104 employees
MRVI vs TRAX FAQ
Which is bigger, Maravai LifeSciences or First Tracks Biotherapeutics?
Maravai LifeSciences (MRVI) is larger, with a market capitalization of $1.81B compared with $1.75B for First Tracks Biotherapeutics (TRAX).
Are Maravai LifeSciences and First Tracks Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.